590417-94-0

Usage

Uses

Used in Chemical Research:
6-Bromo-1-methyl-1H-indazole is used as a chemical compound in research for its unique properties and potential applications in various chemical processes.
Used in Pharmaceutical Development:
6-Bromo-1-methyl-1H-indazole is used as a building block in the synthesis of new drugs and pharmaceutical compounds, contributing to the development of innovative medications.
Used in Medicinal Chemistry:
6-Bromo-1-methyl-1H-indazole is used as a key component in the development of antiviral, antibacterial, and anticancer drugs, owing to its potential therapeutic properties.
Used in the Development of New Materials:
6-Bromo-1-methyl-1H-indazole is utilized in the creation of various molecules and can be employed in the development of new materials with unique properties and applications.
Used in Chemical Processes:
6-Bromo-1-methyl-1H-indazole is used as a component in various chemical processes, where its specific characteristics can be leveraged to achieve desired outcomes in chemical reactions and synthesis.

InChI:InChI=1/C8H7BrN2/c1-11-8-4-7(9)3-2-6(8)5-10-11/h2-5H,1H3

Upstream product

• 79762-54-2 6-bromo-1H-indazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1159511-25-7 1-(1-methyl-1H-indazol-6-yl)ethan-1-one 
• 1007219-73-9 1-methyl-1H-indazole-6-carboxylic acid methyl ester 
• 267413-29-6 1-methyl-1H-indazole-6-carbonitrile 
• 1256359-09-7 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors

In previous work, we described 6-6‘-bisindole compounds targeting a hydrophobic pocket on the N-heptad repeat region of viral glycoprotein-41 as effective inhibitors of HIV-1 fusion. Two promising compounds with sub-micromolar IC50's contained a benzoic acid group and a benzoic acid ester attached at the two indole nitrogens. Here we have conducted a thorough structure-activity relationship (SAR) study evaluating the contribution of each of the ring systems and various substituents to compound potency. Hydrophobicity, polarity and charge were varied to produce 35 new compounds that were evaluated in binding, cell-cell fusion and viral infectivity assays. We found that (a) activity based solely on increasing hydrophobic content plateaued at ～ 200 nM; (b) the bisindole scaffold surpassed other heterocyclic ring systems in efficacy; (c) a polar interaction possibly involving Gln575 in the pocket could supplant less specific hydrophobic interactions; and (d) the benzoic acid ester moiety did not appear to form specific contacts with the pocket. The importance of this hydrophobic group to compound potency suggests a mechanism whereby it might interact with a tertiary component during fusion, such as membrane. A promising small molecule 10b with sub-μM activity was discovered with molecular weight 500 da and reduced logP compared to earlier compounds. The work provides insight into requirements for small molecule inhibition of HIV-1 fusion.

AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES

The present invention provides a compound of Formula (I) or Formula (II): enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula (I) and (II) are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).